Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Celgene Corporation has said that phase III testing of its multiple myeloma drug Revlimid, has revealed that it induces a stronger survival benefit when combined with a lose dose steroid than when added to a higher steroid dose.
Subscribe to our email newsletter
The preliminary results showed the drug was tested in patients with newly diagnosed multiple myeloma and combined with the steroid dexamethasone (Decadron) to treat the disease.
Revlimid is approved by the FDA for use as a treatment in combination with standard-dose dexamethasone for patients with multiple myeloma who have received at least one prior therapy. Revlimid is also approved for the treatment of patients with transfusion-dependent anemia.
Revlimid recently received a positive opinion from the European Medicines Agency for use in combination with dexamethasone, as a treatment for patients with multiple myeloma who have received at least one prior therapy.